It is odd for other researchers to not pick up promising research areas from others. |
I think that there was research interest in this but it was extremely premature for Trump and RFK Jr to leap over all the normal processes. Arguably there was less incentive to research this med because it was generic already. But … ya know … Trump and RFK could have announced that they were funding such research instead of what they actually did. |
DP. Conducting the best research doesn't have to mean also waiting years before trying safe drugs. |
You know what actually would have been great for RFK Jr to do? Announce an effort to assess which research efforts have the most potential and deserve the most federal funding. The search for genetic causes has taken up too much bandwidth - perhaps it is time to move on from that. perhaps it is time to focus less on the search for causes and more on effective therapies and treatments. Or perhaps it is time to redefine the categories so scientists can search for the causes of the more disabling forms of autism. But of course, this kind of effort would take time and resources and not allow brainworm to pretend like he alone was conquering the evil FDA. |
Yes it actually does. I’m not sure how many times you need that repeated. |
That's not how grant programs work. They fund projects from the proposals submitted. If no one submitted a Leucovorin trial proposal, they couldn't fund one through the ADSI. Maybe they'll get one next year based on this. But trials take time. And kids don't have time to waste. |
It really doesn't. When to start using a drug is based on risk-benefit. This is a low-risk drug with promising benefits. |
You trust a centralized effort to do that more than distributed grant proposal reviews by subject matter experts? |
So you’re saying the FDA has no ability to create research priorities and strategically fund? Yeah right. And kids don’t have time to take untested and potentially harmful medications. Kids with autism are not guinea pigs and there is a LONG shameful history of subjecting them to untested and harmful therapies and medications. |
Dude. You’re acting like the president and the head of HHS have no power to strategically shape federal and federally funded research. I can’t figure out if you are ignorant or doing this on purpose. |
Other researchers have looking at Leucovorin but there doesn't seem to much research on the folate receptor autoantibody association.. |
|
RFK jr himself has said, “I don’t think people should be taking medical advice from me.”
So there you are, come to your own conclusions. RFK jr seemingly has told trump thet melania caused Baron’s condition and recommended leucovorin. I guess trump thinks it worked. |
No it is is not. It is an untested drug and we don’t know the risks and benefits for the class of kids it is being targeted to. I’m just going to quote the actual research experts again here: “ The September 22 press conference held by U.S. Health and Human Services alarms us researchers … The data cited do not support the claim that Tylenol causes autism and leucovorin is a cure, and only stoke fear and falsely suggest hope when there is no simple answer.” “With this in mind,” the group added, “we do not support any recommendation from the HHS or FDA regarding increased use of folinic acid. Instead, we call for a well-designed, large scale clinical trial of leucovorin (folinic acid) with all of the rigor needed (biomarkers, proper endpoints) and, most importantly, a pre-registered analysis plan.” https://www.thetransmitter.org/spectrum/autism-experts-question-hhs-statements-on-tylenol-leucovorin/ |
They certainly do. And they certainly have. What I don't get is why you want them to do that even more versus having the grant reviewers rate them on their merits. I'd admit I haven't been a part of FDA or NIH grant review proposes, but I've done a part of them at several other agencies. I imagine it is similar. I don't think you understand the process of how grants get funded. |
It's not an "untested drug". The quality of the data is limited, but it isn't untested. Safety trials very frequently don't closely match the expected or intended population. The efficacy trials have been small, but at least four RCTs have had positive results. |